On Wednesday, BioHarvest Sciences (NASDAQ:BHST) announced a new partnership with Tate & Lyle Plc to develop the next generation of proprietary plant-based molecules.

The company said the partnership addressed the increasing consumer desire for affordable, nutritious, and more sustainable plant-derived food and beverage ingredients.

BioHarvest's Botanical Synthesis platform produces non-GMO plant-derived ingredients in a sustainable and economically viable way, helping to scale up the production of highly beneficial botanical ingredients, the company adds.

This proprietary process, which delivers patentable molecules by growing targeted plant cells, can mirror and magnify the phytonutrients contained in specific plants, delivering all the benefits of the plant without having to grow the plant, bioHarvest said in the press release.

Also Read: Aurora's Self-Driving Trucks Poised for Growth, Analyst Forecasts Considerable Upside

The new partnership between Tate & Lyle and BioHarvest will focus on developing the next generation of sweeteners – botanical sweetening ingredients using plant-derived molecules.

Along with the BioHarvest platform, this will meet consumer desire for a sugar-like taste—with no aftertaste—and enable a wider population to have more choices when accessing healthier product ingredients.

According to BioHarvest, the ingredient solutions will be more affordable to the food and beverage industry. They use a fraction of the land and water required in traditional extraction and land-based growing practices.

Tate & Lyle brings its broad portfolio of sugar reduction solutions, regulatory expertise, and access to global customers to the partnership, which forms part of Tate & Lyle's ongoing open innovation program.

Tate & Lyle's Chief Science and Innovation Officer, Victoria Spadaro-Grant, said the initial exploration will focus on its sweetener platform. Still, the partnership also provides for expansion into other areas.

BioHarvest Sciences Ilan Sobel expects Tate & Lyle's regulatory and nutrition expertise, industry knowledge, and complementary research initiatives to help expedite and commercialize the next generation of plant-based molecules developed through its Botanical Synthesis platform.

Price Action: BHST stock closed higher by 3.29% at $6.28 Tuesday.

Also Read:

• C3.ai's Growth Boosted by Microsoft Partnership And AI Expansion Drive, Analysts Up Price Forecast